Sales of Eli Lilly's Mounjaro and Zepbound have surged significantly, widening the company's lead over Novo Nordisk. This was reported by Qazaqyia.kz citing Reuters.
According to Reuters, sales of these two Lilly drugs have risen sharply. This has strengthened the company's leadership in the diabetes and obesity drug market. Compared to Novo Nordisk, Lilly's share is increasing.
Exact figures and financial details are not provided, but the upward trend in sales is clear. This news highlights intensifying competition in the pharmaceutical market.